Astrazeneca Covid19 Vaccine

 Astrazeneca Covid19 Vaccine

Europe's medical regulator is set to give its verdict on the safety of the astrazeneca covid19 vaccine after concerns about blood clots.  At least 13European member states including Germany and France have suspended use of the shot pending the verdict and the European medical agency is investigating reports of 30 unusual blood disorders out of 5 million people who have received the first shot in the Europe so far the regulator has said that it believes that there's no indication of a serious problem though astrazeneca's rollout in Europe has been hit by problems from the start at the end of january Germany ruled that the vaccine should not be given to over 65 due to a lack of data and just a day later the European medicines agency approved use for all adults and germany reversed its earlier decision and then a week ago Denmark became the first country to suspend the astrazeneca vaccine after a 60 year old woman died from blood clot complications. Austria and Norway also paused their own rollouts Germany, Italy and France followed in Asia, Thailand was first to suspend the shot but only briefly Indonesia was also put their rollout on hold as well. Now astrazeneca maintains the shot is safe and it is backed by the who which says that it's better to take the vaccine than not. The astrazeneca shot has also received backing from india it says that it will continue to use the vaccine as infections reach a three-month high.The oxford’s astrazeneca jab is sold in india under the name Covishield it's the primary vaccine that india is using at the moment the aim is to vaccinate 300 million by August. Authorities here are sticking to it and I again assure you that we have no signal of concern in this regard and therefore clearly our program with Covishield implementation Covishield vaccination in the country will go on with full vigor. Authorities argue that so far a causal relationship between the vaccine and blood clots has not been established and scientists here are monitoring the situation experts say the benefits of continuing with the vaccine significantly outweigh the risks.